Evidence That Proton-Pump Inhibitor Therapy Induces the Symptoms it Is Used to Treat

Gastroenterology

Volumn 137, Issue 1, 2009, Pages 20-22

  McColl, Kenneth E L ^a   Gillen, Derek ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ B RECEPTOR; ESOMEPRAZOLE; GASTRIN; HISTAMINE; PLACEBO; PROTON PUMP INHIBITOR;

CLINICAL TRIAL; DRUG WITHDRAWAL; DYSPEPSIA; EDITORIAL; ENTEROCHROMAFFIN LIKE CELL; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; HYPERGASTRINEMIA; HYPERPLASIA; NONHUMAN; PRIORITY JOURNAL; REBOUND; REBOUND ACID HYPERSECRETION; STOMACH ACID SECRETION; STOMACH DISEASE; STOMACH PARIETAL CELL; STOMACH PH;

EID: 67649217255     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.05.015     Document Type: Editorial

References (20)

1. Danish Medicines Agency. Medicinal product statistics in Denmark 2007 (2008), Danish Medicines Agency, Copenhagen
2. Forgacs I., and Loganayagam A. Over-prescribing proton pump inhibitors. BMJ 336 (2008) 2-3
3. Reimer C., Søndergaard B., Hilsted L., et al. Proton pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 137 (2009) 80-87
4. Gillen D., Wirz A.A., Neithercut W.D., et al. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 44 (1999) 468-475
5. Kuipers E.J., Lundell L., Klinkenberg-Knol E., et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 334 (1996) 1018-1022
6. Larsson H., Carlsson E., Mattsson H., et al. Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 90 (1986) 391-399
7. Carlsson E., Larsson H., Mattsson H., et al. Pharmacology and toxicology of omeprazole-with special reference to the effects on gastric mucosa. Scand J Gastroenterol 21 Suppl 118 (1986) 31-38
8. Waldum H.L., Arnestad J.S., Brenna E., et al. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 39 (1996) 649-653
9. Gillen D., Wirz A.A., Ardill J.E., et al. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 116 (1999) 239-247
10. Gillen D., Wirz A.A., and McColl K.E.L. Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment. Gastroenterology 126 4 (2004) 980-988
11. Niklasson A., Lindstrom L., Simren M., et al. Dyspeptic symptoms development after discontinuation of a proton pump inhibitor: clinical importance of acid-rebound. Gastroenterology 134 Suppl 1 (2008) 797
12. National Institute for Clinical Excellence. NICE Clinical Guideline 17. Dyspepsia-management of dyspepsia in adults in primary care (2004), Author, London
13. Talley N.J., and Vakil N. Guidelines for the management of dyspepsia. Am J Gastroenterol 100 (2005) 2324-2337
14. Talley N.J., Meineche-Schmidt V., Pare P., and National Institute for Clinical Excellence. Efficacy of omeprazole in functional dyspepsia: double-blind, randomised, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 12 (1998) 1055-1065
15. 2-receptor antagonist. Gut 30 (1989) 449-454
16. 2-antagonist withdrawal-a comparative study with nizatidine, ranitidine and famotidine. Aliment Pharmacol Ther 5 (1991) 391-398
17. Smith A.D., Gillen D., Cochran K.M., et al. dyspepsia on withdrawal of ranitidine in previously asymptomatic volunteers. Am J Gastroenterol 94 (1999) 1209-1213
18. Jensen R.T. CCKB/gastrin receptor antagonists: recent advances and potential uses in gastric secretory disorders. Yale J Biol Med 69 (1996) 245-259
19. Murphy M.G., Sytnik B., Kovacs T.O.G., et al. The gastrin-receptor antagonist L-365,260 inhibits stimulated acid secretion in humans. Clin Pharmacol Ther 54 (1993) 533-539
20. Nishida A., Kobayashi-Uchida A., Akuzawa S., et al. Gastrin receptor antagonist YM022 prevents hypersecretion after long-term acid suppression. Am J Physiol 269 (1995) G699-G705